MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414439 | Name: Odapipam

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Odapipam is a benzazepine with high affinity and selectivity for D1-dopamine receptors. Labeled with C-11, it has been used as a PET radiotracer to visualize D1 receptors both in striatal and extrastriatal areas, such as the prefrontal cortex. Odapipam inhibits dopamine D1 receptor binding in vitro with low nanomolar to picomolar dissociation constants. The affinity of [11C]NNC 756 for D1 receptors is 0.18 nM. Odapipam was tested in phase I of clinical trials for the treatment of psychotic disorders, but failed.

Chemical Structure

Odapipam
Odapipam
CAS#131796-63-9

Theoretical Analysis

MedKoo Cat#: 414439

Name: Odapipam

CAS#: 131796-63-9

Chemical Formula: C19H20ClNO2

Exact Mass: 329.1183

Molecular Weight: 329.82

Elemental Analysis: C, 69.19; H, 6.11; Cl, 10.75; N, 4.25; O, 9.70

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Odapipam; NNC756; NNC-756; NNC 756
IUPAC/Chemical Name
( )-(S)-8-Chloro-5-(2,3-dihydro-7-benzofuranyl)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-ol
InChi Key
SKMVRXPBCSTNKE-MRXNPFEDSA-N
InChi Code
InChI=1S/C19H20ClNO2/c1-21-7-5-13-9-17(20)18(22)10-15(13)16(11-21)14-4-2-3-12-6-8-23-19(12)14/h2-4,9-10,16,22H,5-8,11H2,1H3/t16-/m1/s1
SMILES Code
OC1=C(Cl)C=C2CCN(C)C[C@H](C3=C(OCC4)C4=CC=C3)C2=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 329.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Andersen JV, Hansen KT. Normal-phase liquid chromatography-particle-beam mass spectrometry in drug metabolism studies of the dopamine receptor antagonist Odapipam and the muscarine M1 receptor agonist Xanomeline. Xenobiotica. 1997 Sep;27(9):901-12. doi: 10.1080/004982597240073. PMID: 9381731. 2: Hansen KT, Stentoft K. Characterization of benzazepine UDP-glucuronosyl- transferases in laboratory animals and man. Xenobiotica. 1995 Jun;25(6):611-22. doi: 10.3109/00498259509061879. PMID: 7483661. 3: Hagelberg N, Forssell H, Aalto S, Rinne JO, Scheinin H, Taiminen T, Någren K, Eskola O, Jääskeläinen SK. Altered dopamine D2 receptor binding in atypical facial pain. Pain. 2003 Nov;106(1-2):43-8. doi: 10.1016/s0304-3959(03)00275-6. PMID: 14581109. 4: Hagelberg N, Forssell H, Rinne JO, Scheinin H, Taiminen T, Aalto S, Luutonen S, Någren K, Jääskeläinen S. Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain. 2003 Jan;101(1-2):149-54. doi: 10.1016/s0304-3959(02)00323-8. PMID: 12507709. 5: Pascoe PJ, Taylor PM. Effects of dopamine antagonists on alfentanil-induced locomotor activity in horses. Vet Anaesth Analg. 2003 Jul;30(3):165-71. doi: 10.1046/j.1467-2995.2003.00134.x. PMID: 14498848. 6: Andersen PH, Grønvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB. NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. Eur J Pharmacol. 1992 Aug 14;219(1):45-52. doi: 10.1016/0014-2999(92)90578-r. PMID: 1397049. 7: Abi-Dargham A, Simpson N, Kegeles L, Parsey R, Hwang DR, Anjilvel S, Zea- Ponce Y, Lombardo I, Van Heertum R, Mann JJ, Foged C, Halldin C, Laruelle M. PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse. 1999 May;32(2):93-109. doi: 10.1002/(SICI)1098-2396(199905)32:2<93::AID-SYN3>3.0.CO;2-C. PMID: 10231129. 8: Laihinen AO, Rinne JO, Ruottinen HM, Någren KA, Lehikoinen PK, Oikonen VJ, Ruotsalainen UH, Rinne UK. PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756. J Nucl Med. 1994 Dec;35(12):1916-20. PMID: 7989969. 9: Peacock L, Hansen L, Mørkeberg F, Gerlach J. Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects. Neuropsychopharmacology. 1999 Jan;20(1):35-43. doi: 10.1016/S0893-133X(98)00049-9. PMID: 9885783. 10: Hansen KT, Thomsen KF, Bundgaard H. Glucuronidation of the dopamine D-1 receptor antagonists NNC 0756 and NNC 0772 in liver microsomes. Drug Metab Dispos. 1992 Mar-Apr;20(2):172-8. PMID: 1352206.